The MHRA has approved vorasidenib (Voranigo) for patients aged 12 and above with grade 2 astrocytoma or oligodendroglioma harbouring a susceptible IDH1 or IDH2 mutation. These tumours originate in glial cells and are driven by mutations in IDH1 or IDH2 genes. Approval was granted through Project Orbis, a global regulatory initiative led by the US FDA and involving agencies in Australia, Canada, Singapore, Switzerland, Brazil and Israel. As with all products, we will keep the safety of this medicine under close review.”Vorasidenib is taken orally once daily. Those treated with vorasidenib showed significantly longer progression-free survival—27.7 months compared to 11.1 months for placebo.